

BRIDLINGTON PRIMARY CARE NETWORK CKD JOINT WORKING

Executive Summary Out Puts

GB 50363

Astra Zeneca and Bridlington Primary Care Network (PCN) entered into a Joint working agreement “The Bridlington Chronic Kidney Disease (CKD) Project”. To review the CKD registry and implement an Algorithm of care to improve CKD patient’s outcomes across the PCN. This project was commissioned in 1st Jan 2022 and terminated on 1st May 2022.

This project delivered:

- Develop and create a Pathway for CKD in Primary care.
- Developing a working pathway using National Institute for Health & Care Excellence (NICE) and Kidney Disease Improving Global Outcomes (KIDGO) guidance with the input of Secondary and primary care in the area.
- At the end of the project this Pathway will be reviewed to ensure it meets the local needs and is robust enough to deliver the desired behaviours and outcomes.
- Robust Code cleansing and case finding to identify suitable patients for CKD Register to optimise Quality & Outcomes Framework (QOF).
- A code cleansing review will be completed capturing all patients who have had Estimated Glomerular Filtration Rate (eGFR), Urine tests, Blood tests or imagery tests to indicate CKD.
- Case Findings will include all Patients who have Diabetes and Heart Failure and those with a family history of CKD.

Review and optimise all identified patients who need, lifestyle change counselling, medication review to prevent progression of the disease and enhance patient outcomes.

- All identified patients will be categorised into recoding those patients who are incorrectly coded and must be added to QOF Register and flag on patient’s notes to assess the progression of the disease using eGFR.
- Review and optimisation of medication and care. This will be conducted by an Integrated Care System (ICS) Grade 8 Pharmacist which will be contracted by the PCN.
- Appropriate lifestyle advice counselling by Dietician or other trained Health Care Professionals (HCPs) in Practice.
- Medicine review by an ICS Pharmacist working within the practice.
- NHS-led Imbedding learnings with a site meeting with all Prescribing HCPs to ensure a legacy of patient care.
- A Training and Review meeting will be held at the end of the project to review.

- This day will be led By Dr Mohamed a Local Consultant and will involve the Pharmacist who delivered the Pilot, learnings and discuss best practices for all HCPs in the Practice.

Care Pathway.

The Algorithm of care was devised before the project started and implemented NICE and pre-existing guidance.

Summary of The Joint Working CKD project.

Bridlington PCN developed a new tool with Oberoi that helped to identify new CKD patients and that needed optimisation of (Angiotensin Converting Enzyme inhibitors, Angiotensin II Receptor Beta Blockers, Mineralocorticoid Receptor Antagonists & Angiotensin Receptor/ neprilysin inhibitor ('RAASi') therapy and Dapagliflozin.

All identified CKD patients were stratified into the KDIGO risk chart. NICE NG203 and Leeds CKD guidelines were then enacted for the medicine's optimisation of identified patients. In the period of the project 75 patients were initiated on new standards of care as a direct result of this project.

The ongoing legacy of this project is a base line of an optimised CKD register, the continued engagement of all staff in the project Algorithm to optimise all existing / new patients to this standard of care.